精神药物的治疗监测：AGNP-TDM专家组共识指南概述。
Therapeutic monitoring of psychotropic drugs: an outline of the AGNP-TDM expert group consensus guideline.
作者信息
Baumann P, Hiemke C, Ulrich S, Gaertner I, Rao M L, Eckermann G, Gerlach M, Kuss H J, Laux G, Müller-Oerlinghausen B, Riederer P, Zernig G
机构信息
Unité de Biochimie et Psychopharmacologie Clinique, Département Universitaire de Psychiatrie Adulte, CH-1008 Prilly-Lausanne, Switzerland.
出版信息
Ther Drug Monit. 2004 Apr;26(2):167-70. doi: 10.1097/00007691-200404000-00014.
TDM of psychotropic drugs is widely used, but there is little consensus regarding its optimal use in the clinical context. This prompted a multidisciplinary group comprised of clinical biochemists, clinical pharmacologists, and psychiatrists of the AGNP (Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie) to provide a consensus guideline. This will allow clinical psychiatrists, practitioners, and laboratory directors involved in psychopharmacotherapy to optimize TDM of antidepressants, antipsychotics, and opioid substituents. Recommendations are also given on the combined use of TDM and pharmacogenetic tests.
精神药物的血药浓度监测（TDM）被广泛应用，但在临床环境中关于其最佳使用方法却几乎没有共识。这促使由AGNP（神经精神药理学和药物精神病学工作组）的临床生物化学家、临床药理学家和精神科医生组成的多学科小组制定了一项共识指南。这将使参与精神药物治疗的临床精神科医生、从业者和实验室主任能够优化抗抑郁药、抗精神病药和阿片类替代药物的TDM。同时还给出了关于TDM与药物遗传学检测联合使用的建议。
Zotero 插件